HR Execs on the Move

Acupuncture Association

www.acupuncture-quebec.com

 
Acupuncture Association is a Longueuil, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cybermedx Medical Systems

Cybermedx Medical Systems is a Lebanon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alicare Medical Management

Alicare Medical Management is a West Harrison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Roberts Home Medical

Roberts Home Medical, Inc. is a Harrisonburg, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Premier Research

We`re out to change the course of medical science. Are you ready to rise to the challenge? Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today`s biotech and specialty pharma pioneers are doing the most amazing work. We`re 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers` most challenging needs. Join us and meet some of the brightest minds in clinical development today — people who apply their best thinking to every project, recognizing that what they do significantly affects the lives and well-being of customers, patients, physicians, and colleagues. You`ll enjoy great benefits and very flexible working conditions in a company that values your contributions, rewards your achievements, and is committed to helping you reach your full potential.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.